Abstract
Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a prognostic marker and as a molecular target for cancer therapy.
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Anti-Cancer Agents in Medicinal Chemistry
Title:RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Volume: 12 Issue: 7
Author(s): Siddavaram Nagini
Affiliation:
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Abstract: Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a prognostic marker and as a molecular target for cancer therapy.
Export Options
About this article
Cite this article as:
Nagini Siddavaram, RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review), Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650237
DOI https://dx.doi.org/10.2174/187152012802650237 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Network Pharmacology and Reverse Molecular Docking-Based Prediction of the Molecular Targets and Pathways for Avicularin Against Cancer
Combinatorial Chemistry & High Throughput Screening NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Palladacycles as Antimicrobial Agents
Current Medicinal Chemistry The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Indoles and Related Compounds as Cannabinoid Ligands
Mini-Reviews in Medicinal Chemistry Gender Disparity in Pediatric Diseases
Current Molecular Medicine Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Terpenes with Antitumor Activity: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery